The study sponsored by Haikou Affiliated Hospital of Central South University aims to elucidate the pathogenic mechanisms underlying bronchiolitis obliterans syndrome (BOS) and explore targeted therapeutic strategies. Given the increasing prevalence of BOS post-hematopoietic stem cell transplantation, this research addresses a significant unmet medical need, potentially positioning the sponsor as a leader in innovative treatments for BOS. The findings could lead to novel therapeutic interventions, enhancing patient outcomes and quality of life, which may attract interest from pharmaceutical companies looking to expand their respiratory disease portfolios. Competitive implications include the potential for partnerships or licensing agreements, particularly if the research yields promising results that can be translated into clinical applications.